Stomach balloon study aims to help people with obesity shed pounds safely

NCT ID NCT07062094

Recruiting now Disease control Sponsor: Boston Scientific Corporation Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 4 times

Summary

This study tracks 200 adults with obesity in the EU who choose to get the Orbera365 intragastric balloon. The balloon is placed in the stomach and filled with saline to help people feel full and eat less. Researchers will monitor serious side effects and how much weight participants lose over up to 12 months with the balloon in place.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: intragastric balloon (Orbera365)
What this could lead to: If successful, this could confirm that the Orbera365 balloon is a safe and effective tool for significant weight loss in people with obesity.
What could go wrong: This is an observational registry, not a controlled trial, so results may be less definitive. Risks include serious complications like blockage or balloon deflation requiring hospital care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY

Contacts and locations

Locations

Dorsia Clinic, Madrid Spain
RECRUITING

Madrid, Spain
EndoBes - Centre Medico Teknon
RECRUITING

Barcelona, Spain
OB Klinika
RECRUITING

Prague, Czechia
UHCW NHS Trust
NOT_YET_RECRUITING

Coventry, West Midlands, CV2 2DX, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.